Hong Kong Pharma Digital Technology Holdings Ltd. has released its annual financial results for the fiscal year ending March 31, 2025. The company reported a net profit of $1.33 million, marking a significant increase of 33% from the previous year's net profit of $998,196. The gross profit for the year amounted to $3.56 million, up 30% from the prior period's $2.74 million. Cost of revenues rose by 34% to $13.13 million from $9.82 million in the previous year. Selling, general, and administrative expenses increased by 7% to $1.89 million compared to $1.76 million the year before. The company's profit before income taxes was $1.53 million, reflecting a 49% increase from the prior fiscal year's $1.02 million. Income tax expenses were reported at $196,252, up from $22,574. Hong Kong Pharma attributes its financial performance to factors such as maintaining a competitive value proposition, key customer relationships, and successful marketing and sales activities. The company continues to focus on adapting its supply chain and securing financial resources at favorable terms. No specific outlook or guidance for future performance was provided in the report.